Results 171 to 180 of about 65,592 (243)

Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real‐World Data From the LOR‐HCC (Lombardy Real‐World HCC Group)

Liver International, Volume 46, Issue 5, May 2026.
ABSTRACT Background and Aim Dual immune checkpoint blockade with tremelimumab plus durvalumab (STRIDE) is an established first‐line therapy for unresectable hepatocellular carcinoma (uHCC); however, real‐world evidence on its safety, toxicity kinetics and liver function dynamics remains limited.
Andrea Casadei‐Gardini, Lorenzo Canova, Federica Tosi, Silvia Camera, Elisa Bocchero, Pietro Pozzoni, Martina Torchio, Salvatore Corallo, Daniela Costantino, Annamaria Stagno, Giulia Grizzi, Rita Gengarle, Gianluca Tomasello, Nasim Ansarin, Mariangela Bruccoleri, Katia Bencardino, Mara Persano, Martina Pino, Alessia Riva, Sara Vavassori, Lorenzo Argiento, Chiara Mazzarelli, Massimo De Giorgio, Elena Rota Caremoli, Margherita Rimini, Tiziana Pressiani, Lorenza Rimassa, Massimo Iavarone   +27 more
wiley   +1 more source

Characterization of long‐term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021

International Journal of Cancer, Volume 158, Issue 8, Page 2179-2185, 15 April 2026.
What's New? Liver metastasis is an indicator of life expectancy for patients with advanced uveal melanoma (UM). Data on anticipated survival time following the diagnosis of liver metastasis, however, is lacking. The present study analyzed long‐term survival among UM patients who lived three or more years after liver metastases were diagnosed.
Jona Laukhuf, Lisa Wiens, Gerd Grözinger, Helmut Dittmann, Karolin Thiel, Ulrike Leiter, Teresa Amaral, Lena Nanz, Lukas Flatz, Markus Reitmajer, Andrea Forschner   +10 more
wiley   +1 more source

Advanced Mucosal Melanoma Therapies: Current Status and Future Directions. [PDF]

Curr Treat Options Oncol
Zhang Y, Zhao D, Wu D.
europepmc   +1 more source

First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial. [PDF]

Nat Commun
Lorenzen S, Goetze TO, Thuss-Patience PC, Riera-Knorrenschild J, Goekkurt E, Dechow TN, Ettrich TJ, Hofheinz RD, Luley KB, Pink D, Lindig U, Folprecht G, Schuch G, Bitzer M, Heinemann V, Angermeier S, Bolling C, Loose M, Junge S, Pauligk C, Al-Batran SE.   +20 more
europepmc   +1 more source

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0. [PDF]

J Immunother Cancer
McKay RR, Ajmera A, Atkins MB, Barata PC, Bergerot C, Bukavina L, Choueiri TK, Desai A, Hakimi AA, Poteat S, Powles T, Rini BI, Shuch B, Signoretti S, Siva S, Xu W, Yip W, Zhang T, Pal SK.   +18 more
europepmc   +1 more source

Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinoma. [PDF]

J Immunother Cancer
Grewal K, Moura Nascimento Santos MJ, Chauhan PK, Yu K, Tannir NM, Mukhida SS, Venkatesh N, Shah AY, Zurita AJ, Johns AC, Campbell MT, Goswami S, Gao J, Jonasch E, McQuade JL, Alhalabi O, Msaouel P, Hahn AW.   +17 more
europepmc   +1 more source

Correction: Comparison of real-world efficacy and safety of nivolumab plus ipilimumab or pembrolizumab combined with platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer in a German population. [PDF]

Cancer Immunol Immunother
Weber M, von Hammerstein-Equord AF, Weinreich M, Andreas S, Rittmeyer A.   +4 more
europepmc   +1 more source

Incidence and Comparative Risk of Hematological Adverse Events Across Different Immune Checkpoint Inhibitors: A Network Meta-Analysis of Randomized Controlled Trials. [PDF]

Cureus
Vajje J, Reyaz N, Gillani I, Muneeb Ullah M, Chaudhari SS, Jabeen S, Wei CR, Amin A.   +7 more
europepmc   +1 more source

A Systematic Review of Ipilimumab-Induced Hypophysitis. [PDF]

Endocr Connect
Kim S, Yadav Teerupati SN, Rissardo JP, Patel P, Lai E, Byroju VV, Fornari Caprara AL.   +6 more
europepmc   +1 more source

Immunotherapy advances in pleural mesothelioma. [PDF]

Ther Adv Med Oncol
Zhang AL, Hsu ML.
europepmc   +1 more source